CRNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Crinetics Pharmaceuticals Inc (CRNX) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. The stock is exhibiting bearish technical indicators, no strong proprietary trading signals, and mixed catalysts. While there is positive sentiment from analysts and hedge fund buying, the company's financial performance remains weak, and insider selling is a notable red flag. Given the investor's impatience and unwillingness to wait for optimal entry points, holding off on this investment is advisable.
The stock is showing bearish technical indicators. The MACD is negatively expanding below 0, the RSI is neutral at 24.005, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The current price of $35.78 is near the S1 support level of $35.746, but there is no clear signal for a reversal or upward momentum.
Hedge funds are significantly increasing their buying activity, up 448.61% over the last quarter.
Analysts maintain an optimistic outlook with multiple Buy and Outperform ratings, and price targets remain significantly higher than the current price, ranging from $83 to $
The Palsonify launch in Acromegaly and the atumelnant updates in CAH are seen as strong growth drivers with high potential for blockbuster success.
Insiders are selling heavily, with a 1466.99% increase in selling activity over the last month.
The stock's technical indicators are bearish, and there is no clear upward momentum.
The company's financials show continued losses, with Q4 2025 net income at -$122.8M and EPS at -1.29, despite YoY improvements.
No recent news or significant event-driven catalysts to support a near-term price increase.
In Q4 2025, revenue remained flat YoY at $6.16M. Net income improved by 52.39% YoY but remains deeply negative at -$122.8M. EPS improved by 46.59% YoY to -1.29. Gross margin dropped significantly by -17.46% YoY to 82.54%. Overall, the company is still in a loss-making phase with no immediate signs of profitability.
Analysts maintain a positive outlook with multiple Buy and Outperform ratings. Recent price target adjustments show slight reductions but remain significantly higher than the current price, ranging from $83 to $97. Analysts highlight strong execution in the Palsonify launch and pipeline development, but there are concerns about competition in the CAH market.
